Reducing the YAP1 expression, along with a double hit on the TCA cycle—depleting the essential molecule acetyl CoA via HDAC inhibition and blocking key intermediate steps dependent on NAD cofactors via NAMPT inhibition could be highly effective in neuroendocrine neoplasms and should be pursued with a goal of developing translational clinical trials. This evidence concerns the gene YAP1 and neuroendocrine neoplasm.